Silexion Therapeutics Reports $7.5 Million Net Loss for Nine-Month Period Ending September 30, 2025

Silexion Therapeutics Corp reported its financial results for the nine-month period ending September 30, 2025, revealing a net loss of $7.5 million, a significant decrease from the $14.8 million loss recorded during the same period in 2024. The company's total operating expenses for the nine months were $7.2 million, down from $10.7 million in the previous year. This reduction was primarily attributed to lower research and development costs, which fell to $3.8 million from $4.9 million, and a decrease in general and administrative expenses, which dropped to $3.5 million from $5.7 million. The decrease in expenses was largely due to a reduction in non-cash share-based compensation.

In terms of liquidity, Silexion reported cash and cash equivalents of $9.2 million as of September 30, 2025, a notable increase from $1.3 million at the beginning of the year. The company raised approximately $15.9 million in financing activities during the nine-month period, primarily through public offerings and warrant exercises. This included gross proceeds of $5 million from a public offering in January 2025 and $6 million from another offering in September 2025. The company also entered into an At The Market Offering Agreement, allowing for the potential sale of up to $13.17 million in ordinary shares.

Silexion's operational focus remains on advancing its lead product candidate, SIL204, which targets the KRAS oncogene associated with various cancers, including pancreatic cancer. The company is preparing for clinical trials contingent upon regulatory approvals. As part of its strategic developments, Silexion has onboarded external vendors to enhance operational readiness and is actively pursuing additional financing options to support its research and development efforts.

Despite the positive trends in reducing losses and increasing cash reserves, Silexion's management expressed substantial doubt about the company's ability to continue as a going concern without additional financing. The company has not yet generated revenue and anticipates ongoing operating losses as it continues to invest in the development of SIL204 and other potential product candidates. The management is evaluating various financing alternatives to ensure the sustainability of operations in the coming year.